November 1, 2021 -- BioNTech plans to highlight new clinical data from a phase I/II trial of its BNT211 CAR T-cell therapy candidate at the Society for Immunotherapy of Cancer meeting in Washington, DC, on November 12.
BNT211 is an autologous CAR T-cell therapy that targets oncofetal antigen claudin 6 (CLDN6), according to the company. BNT211 is currently in trials for assessment as a monotherapy, as well as in combination with a CLDN6 mRNA-based vaccine (CARVac), for the treatment of relapsed or refractory advanced solid tumors, BioNTech said.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: